From Targeted Therapy to Immune Checkpoint Inhibition
(UroToday.com) The 2020 American Society of Clinical Oncology (ASCO) virtual education program featured a session on the evolution of renal cell carcinoma (RCC) treatment, including a presentation by renowned oncologist Dr. Bernard Escudier discussing the evolution from targeted therapy to immune checkpoint inhibition. The rationale for antiangiogenic therapy in RCC is that RCC is a tremendously vascular […]
